Ocular Therapeutix (OCUL) Shares Outstanding (Weighted Average) (2013 - 2026)
Ocular Therapeutix's quarterly Shares Outstanding (Weighted Average) came in at $224.1 million in Q1 2026, up 32.29% year-on-year from $169.4 million in Q1 2025, and up 19.68% quarter-over-quarter from $187.2 million in Q4 2025.
Ocular Therapeutix has reported Shares Outstanding (Weighted Average) for 14 years, with the latest figure at $224.1 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 32.29% year-over-year to $224.1 million; the trailing twelve-month figure through Mar 2026 stood at $224.1 million (up 32.29% YoY), and the FY2025 full-year result was $187.2 million, up 18.31% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $224.1 million, up from $187.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $224.1 million in Q1 2026, with the low at $76.7 million in Q1 2022.
- Average Shares Outstanding (Weighted Average) over 5 years is $127.7 million, with a median of $132.0 million recorded in 2024.
- Year-over-year, Shares Outstanding (Weighted Average) rose 0.36% in 2022 and soared 112.47% in 2024.
- Tracing OCUL's Shares Outstanding (Weighted Average) over 5 years: stood at $76.9 million in 2022, then gained by 3.84% to $79.8 million in 2023, then jumped by 98.26% to $158.3 million in 2024, then advanced by 18.31% to $187.2 million in 2025, then gained by 19.68% to $224.1 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $224.1 million (Q1 2026), $187.2 million (Q4 2025), and $183.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 224.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 224.10 Mn |
| Dec 31, 2025 | 187.24 Mn |
| Sep 30, 2025 | 183.92 Mn |
| Jun 30, 2025 | 172.59 Mn |
| Mar 31, 2025 | 169.40 Mn |
| Dec 31, 2024 | 158.27 Mn |
| Sep 30, 2024 | 154.99 Mn |
| Jun 30, 2024 | 165.82 Mn |
| Mar 31, 2024 | 132.02 Mn |
| Dec 31, 2023 | 79.83 Mn |
| Sep 30, 2023 | 79.37 Mn |
| Jun 30, 2023 | 78.05 Mn |
| Mar 31, 2023 | 77.39 Mn |
| Dec 31, 2022 | 76.88 Mn |
| Sep 30, 2022 | 76.83 Mn |
| Jun 30, 2022 | 76.76 Mn |
| Mar 31, 2022 | 76.75 Mn |
| Dec 31, 2021 | 76.39 Mn |
| Sep 30, 2021 | 76.55 Mn |
| Jun 30, 2021 | 76.32 Mn |
| Mar 31, 2021 | 76.07 Mn |
| Dec 31, 2020 | 60.75 Mn |
| Sep 30, 2020 | 62.99 Mn |
| Jun 30, 2020 | 54.63 Mn |
| Mar 31, 2020 | 51.90 Mn |
| Dec 31, 2019 | 45.27 Mn |
| Sep 30, 2019 | 46.94 Mn |
| Jun 30, 2019 | 42.91 Mn |
| Mar 31, 2019 | 42.25 Mn |
| Dec 31, 2018 | 38.12 Mn |
| Sep 30, 2018 | 37.11 Mn |
| Jun 30, 2018 | 37.52 Mn |
| Mar 31, 2018 | 34.79 Mn |
| Dec 31, 2017 | 28.82 Mn |
| Sep 30, 2017 | 28.60 Mn |
| Jun 30, 2017 | 28.35 Mn |
| Mar 31, 2017 | 27.64 Mn |
| Dec 31, 2016 | 24.82 Mn |
| Sep 30, 2016 | 24.85 Mn |
| Jun 30, 2016 | 24.76 Mn |
| Mar 31, 2016 | 24.75 Mn |
| Dec 31, 2015 | 23.24 Mn |
| Sep 30, 2015 | 24.71 Mn |
| Jun 30, 2015 | 21.77 Mn |
| Mar 31, 2015 | 21.36 Mn |
| Dec 31, 2014 | 10.65 Mn |
| Sep 30, 2014 | 15.17 Mn |
| Jun 30, 2014 | 3.04 Mn |
| Mar 31, 2014 | 2.86 Mn |
| Dec 31, 2013 | 2.61 Mn |
| Sep 30, 2013 | 2.62 Mn |
| Jun 30, 2013 | 2.60 Mn |